Delving into the Latest Updates on CC-1088 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

CC 1088, CC 801, CC-801

+ [2]

Target

PDE4

Action

inhibitors

Mechanism

PDE4 inhibitors(Phosphodieterase 4 inhibitors)

Therapeutic Areas

Hemic and Lymphatic Diseases

Active Indication-

Inactive Indication

Myelodysplastic Syndromes

Originator Organization

Celgene Corp.

Active Organization-

Inactive Organization

Celgene Corp.

License Organization-

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC23H24N2O5

InChIKeyDDYUBCCTNHWSQM-UHFFFAOYSA-N

CAS Registry192819-27-5

In this communication, we report the discovery of 1S (apremilast), a novel potent and orally active phosphodiesterase 4 (PDE4) and tumor necrosis factor-alpha inhibitor. The optimization of previously reported 3-(1,3-dioxo-1,3-dihydroisoindol-2-yl)-3-(3,4-dimethoxyphenyl)propionic acid PDE4 inhibitors led to this series of sulfone analogues. Evaluation of the structure-activity relationship of substitutions on the phthalimide group led to the discovery of an acetylamino analogue 1S, which is currently in clinical trials.

01 Oct 2006·Bioorganic & medicinal chemistryQ3 · MEDICINE

Development of new CoMFA and CoMSIA 3D-QSAR models for anti-inflammatory phthalimide-containing TNFα modulators

Q3 · MEDICINE

Article

Author: Carlos M.R. Sant’Anna ; Gilberto M. Sperandio da Silva ; Nelilma Correia Romeiro ; Carolina Martins Avila ; Eliezer J. Barreiro ; Carlos A.M. Fraga

In the present study, we describe a new 3D-QSAR analysis of 42 previously reported thalidomide analogues, with the ability to modulate the pro-inflammatory cytokine TNFalpha, by using comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA). Three statistically significant models were obtained. The best resulting CoMFA and CoMSIA models have conventional r(2) values of 0.996 and 0.983, respectively. The cross-validated q(2) values are 0.869 and 0.868, respectively. The analysis of CoMFA and CoMSIA contour maps provided insight into the possible sites for structural modification of the thalidomide analogues for better activity and reduced toxicity.

01 May 2005·Current opinion in investigational drugs (London, England : 2000)

Review

Author: Dredge, Keith

CC-1088, a thalidomide analog inhibitor of phosphodiesterase 4, was being developed by Celgene for the potential treatment of inflammatory diseases and myelodysplastic syndromes, and had undergone clinical trials. By April 2005, however, the company was no longer developing CC-1088, with CC-10004 presumed to be the preferred compound.

100 Deals associated with CC-1088

Login to view more data